文献速递认知障碍与痴呆

临床前与前驱期认知阶段的认知结局临床意义变化:对阿尔茨海默病临床试验的启示

Clinically Relevant Changes for Cognitive Outcomes in Preclinical and Prodromal Cognitive Stages: Implications for Clinical Alzheimer Trials.
PubMed 文献 · Neurology · 2022-07-14

基于瑞典BioFINDER队列,连续纳入认知正常(含主观认知下降)及轻度认知障碍个体,采用锚定法和分布法建立常用认知测验的最小临床重要差值(MCID),并探索预测CDR-SB变化的最佳复合认知指标。研究给出了各测验的MCID范围,并发现包含性别及ADAS延迟回忆、MMSE、SDMT、TMT B变化的复合指标预测CDR-SB变化≥0.5或≥1.0的AUC为0.87。

要点

  • 研究建立认知正常和MCI人群多种认知测验的MCID,供临床试验判断临床相关变化。
  • 预测CDR-SB变化的最佳复合指标含性别及ADAS延迟回忆、MMSE、SDMT、TMT B变化,AUC 0.87。
  • 作者认为MCID可用于临床实践或临床试验识别临床相关变化,复合指标可用于临床前AD试验。

核心结论

  • 研究所建立的MCID可用于临床实践或临床试验中判断是否发生临床相关变化。
  • 包含性别及ADAS延迟回忆、MMSE、SDMT和TMT B变化的复合认知指标可作为临床前AD试验中临床相关的认知结局。

研究设计与样本

  • 来自瑞典BioFINDER队列研究,连续纳入认知正常(含主观认知下降)和轻度认知障碍个体,采用锚定法和分布法计算MCID。
  • 认知正常组451人(主观认知下降90人,无认知下降症状361人),汇总平均随访32.4个月(SD 26.8,范围12-96个月)。
  • 轻度认知障碍组292人,汇总平均随访19.2个月(SD 19.0,范围12-72个月)。
  • 采用受试者工作特征分析探索预测CDR-SB变化≥0.5或≥1.0分的最佳认知指标。

主要发现

  • 认知正常组与MCI组的三角验证MCID分别为:MMSE -1.5、-1.7;ADAS延迟回忆1.4、1.1;Stroop 5.5、9.3。
  • 认知正常组与MCI组的三角验证MCID分别为:动物流畅性-2.8、-2.9;字母S流畅性-2.9、-1.8;SDMT -3.5、-3.8。
  • 认知正常组与MCI组的三角验证MCID分别为:TMT A 11.7、13.0;TMT B 24.4、20.1。
  • 在淀粉样蛋白阳性认知正常者中,预测CDR-SB变化的最佳复合指标包括性别及ADAS延迟回忆、MMSE、SDMT、TMT B的变化,AUC 0.87(95% CI 0.79-0.94,敏感度75%,特异度88%)。

关键数值与推荐

  • 认知正常者MMSE的MCID为-1.5,MCI者为-1.7。
  • 认知正常者ADAS延迟回忆的MCID为1.4,MCI者为1.1。
  • 认知正常者Stroop的MCID为5.5,MCI者为9.3。
  • 认知正常者动物流畅性MCID为-2.8,MCI者为-2.9;字母S流畅性MCID为-2.9、-1.8。
  • 认知正常者SDMT的MCID为-3.5,MCI者为-3.8;TMT A的MCID为11.7、13.0;TMT B的MCID为24.4、20.1。

临床怎么用

  • 作者认为MCID可用于临床实践或临床试验,以识别是否发生临床相关变化。
  • 作者认为复合指标可作为临床前AD试验中临床相关的认知测验结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Identifying a clinically meaningful change in cognitive test score is essential when using cognition as an outcome in clinical trials. This is especially relevant because clinical trials increasingly feature novel composites of cognitive tests. Our primary objective was to establish minimal clinically important differences (MCIDs) for commonly used cognitive tests, using anchor-based and distribution-based methods, and our secondary objective was to investigate a composite cognitive measure that best predicts a minimal change in the Clinical Dementia Rating-Sum of Boxes (CDR-SB). METHODS: From the Swedish BioFINDER cohort study, we consecutively included cognitively unimpaired (CU) individuals with and without subjective or mild cognitive impairment (MCI). We calculated MCIDs associated with a change of ≥0.5 or ≥1.0 on CDR-SB for Mini-Mental State Examination (MMSE), ADAS-Cog delayed recall 10-word list, Stroop, Letter S Fluency, Animal Fluency, Symbol Digit Modalities Test (SDMT) and Trailmaking Test (TMT) A and B, and triangulated MCIDs for clinical use for CU, MCI, and amyloid-positive CU participants. For investigating cognitive measures that best predict a change in CDR-SB of ≥0.5 or ≥1.0 point, we conducted receiver operating characteristic analyses. RESULTS: Our study included 451 cognitively unimpaired individuals, 90 with subjective cognitive decline and 361 without symptoms of cognitive decline (pooled mean follow-up time 32.4 months, SD 26.8, range 12-96 months), and 292 people with MCI (pooled mean follow-up time 19.2 months, SD 19.0, range 12-72 months). We identified potential triangulated MCIDs (cognitively unimpaired; MCI) on a range of cognitive test outcomes: MMSE -1.5, -1.7; ADAS delayed recall 1.4, 1.1; Stroop 5.5, 9.3; Animal Fluency: -2.8, -2.9; Letter S Fluency -2.9, -1.8; SDMT: -3.5, -3.8; TMT A 11.7, 13.0; and TMT B 24.4, 20.1. For amyloid-positive CU, we found the best predicting composite cognitive measure included gender and changes in ADAS delayed recall, MMSE, SDMT, and TMT B. This produced an AUC of 0.87 (95% CI 0.79-0.94, sensitivity 75%, specificity 88%). DISCUSSION: Our MCIDs may be applied in clinical practice or clinical trials for identifying whether a clinically relevant change has occurred. The composite measure can be useful as a clinically relevant cognitive test outcome in preclinical AD trials.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Borland E, Edgar C, Stomrud E, et al. Clinically Relevant Changes for Cognitive Outcomes in Preclinical and Prodromal Cognitive Stages: Implications for Clinical Alzheimer Trials. Neurology. 2022. PMID: 35835560. doi:10.1212/WNL.0000000000200817

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。